Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

AMST

Amesite Inc

Apr 25 • 04:00PM ET

3.50

Dollar change +0.15
Percentage change 4.48	%

Technology • Software - Application • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-1.45	Insider Own	31.67%	Shs Outstand	2.54M	Perf Week	79.46%
Market Cap	8.89M	Forward P/E	-	EPS next Y	-	Insider Trans	1.26%	Shs Float	1.74M	Perf Month	62.78%
Income	-3.67M	PEG	-	EPS next Q	-	Inst Own	3.59%	Short Float	1.17%	Perf Quarter	49.57%
Sales	0.43M	P/S	20.67	EPS this Y	-	Inst Trans	-	Short Ratio	0.02	Perf Half Y	40.20%
Book/sh	1.72	P/B	2.03	EPS next Y	-	ROA	-57.03%	Short Interest	0.02M	Perf Year	-6.42%
Cash/sh	1.44	P/C	2.43	EPS next 5Y	-	ROE	-59.94%	52W Range	1.72 - 5.77	Perf YTD	55.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.35%	ROI	-83.92%	52W High	-39.34%	Beta	1.53
Dividend TTM	-	Quick Ratio	21.92	Sales past 5Y	270.81%	Gross Margin	-41.59%	52W Low	103.49%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	21.92	EPS Y/Y TTM	52.94%	Oper. Margin	-887.29%	RSI (14)	79.86	Volatility	17.44% 8.99%
Employees	14	Debt/Eq	0.00	Sales Y/Y TTM	-51.12%	Profit Margin	-849.47%	Recom	1.00	Target Price	40.80
Option/Short	No / No	LT Debt/Eq	0.00	EPS Q/Q	-28.59%	Payout	-	Rel Volume	1.47	Prev Close	3.35
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-82.52%	Earnings	-	Avg Volume	1.15M	Price	3.50
SMA20	61.25%	SMA50	59.48%	SMA200	37.75%	Trades		Volume	1,691,637	Change	4.48%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Initiated	The Benchmark Company	Speculative Buy	$7

Apr-24-24 07:52AM	Top Premarket Gainers (MT Newswires) +67.50%
07:30AM	Amesite Launches Revolutionary NurseMagic App in Beta to Empower 5.2 Million Nurses with AI Tools (GlobeNewswire)
Mar-21-24 07:30AM	Amesite Announces Strategic Five-Year Partnership with Volunteer State Community College to Expand Technical Workforce (ACCESSWIRE)
Mar-11-24 05:11PM	Amesite Announces Strategic Five-Year Partnership to Expand Workforce Development with Joliet Junior College (GlobeNewswire)
Mar-06-24 07:30AM	Amesite Announces Launch of Active Shooter Preparedness App with World Renowned Expert Chris Grollnek (GlobeNewswire) +5.88%
07:30AM	Loading…
Mar-04-24 07:30AM	Amesite Announces Partnership with PACE to Deliver Accredited Continuing Education for Healthcare Professionals Using Artificial Intelligence-Driven Platform (GlobeNewswire)
Feb-13-24 07:30AM	Amesite Announces New Article Automation Feature, Enabling Continuous Program Updates from 14,000 Academic Sources (GlobeNewswire) +9.88%
Feb-06-24 07:30AM	Amesite Announces Industry-Leading Results on User Retention across Programs, Increase in Sales Activity (GlobeNewswire)
Jan-29-24 07:30AM	Amesite Launches Implicit Bias Training with Expert Larry Davis Jr. (GlobeNewswire) +6.00%
Jan-23-24 01:09PM	Amesite Launches Active Shooter Preparedness Training with Expert Chris Grollnek (GlobeNewswire)
Jan-17-24 11:42AM	Amesite's Announces TX-RAMP Certification, Paving the Way for Transformative Educational Partnerships in Texas (GlobeNewswire) -12.45%
Jan-05-24 10:19AM	Amesite Offering Teacher Training on AI Technology in new Contract with Scottsdale Unified School District (GlobeNewswire) +8.70%
Jan-04-24 02:22PM	Amesite Inc. Partners with Central Michigan University to Launch a Pioneering Asynchronous Implicit Bias Course for Healthcare Professionals (GlobeNewswire)
Dec-12-23 07:30AM	Amesite Announces Strategic Five-Year Partnership to Expand Workforce Development with West Virginia Northern Community College (GlobeNewswire)
Nov-29-23 07:30AM	The NAFEO-Amesite Alliance Announces Strategic Five-Year Partnership to Enhance Workforce Education with Drake State Community College (GlobeNewswire)
07:30AM	Loading…
Nov-06-23 07:30AM	Amesite Announces Partnership Expansion with Benedict College for 5y Term through NAFEO-Amesite Alliance (GlobeNewswire)
Nov-02-23 09:30AM	Amesite Releases Video Shareholder Update (GlobeNewswire)
Oct-23-23 07:30AM	Amesite Announces Partnership with Wayne State University Graduate School (GlobeNewswire)
Oct-10-23 07:30AM	Amesite Announces Launch of 12 Industry 4.0 Courses with Partner, Michigan Works! Southeast (GlobeNewswire) +5.65%
Sep-28-23 07:30AM	Amesite Announces Founder and CEO, Dr. Ann Marie Sastry Delivering Keynote and Company Presentation at LD Micro Main Event XVI (GlobeNewswire)
Aug-15-23 07:30AM	Amesite Announces Partnership Renewal with Central Michigan University (GlobeNewswire)
Aug-02-23 09:06PM	7 AI Stocks to Buy Under $5 in August 2023 (InvestorPlace)
Jul-25-23 07:30AM	Amesite Announces Integration Capability with LMS Platforms, Bringing AI to Organizations with Existing Contract Commitments (GlobeNewswire)
Jul-14-23 09:25AM	The Department Of Education Issues Recommendations For How Educators Should Approach The Use Of AI Benzinga Dives Deeper With EdTech CEO (News Direct) -6.80%
Jul-07-23 07:30AM	Amesites CEO Ann Marie Sastry Special Guest in ARK Invests Podcast (GlobeNewswire)
Jul-06-23 09:00AM	As IMF Deputy Director Issues AI Warning, Workers Are Unprepared For Disruptions Caused By Advent Of AI Amesite Is Looking To Change That (News Direct)
Jun-28-23 07:30AM	Amesite Announces V6.3, with Streamlined, AI-First Infrastructure to Enable Customization and Scale for Its Enterprise Customers (GlobeNewswire) -6.90%
Jun-26-23 07:30AM	Amesite Named One of Michigans 2023 Best and Brightest in Wellness® (GlobeNewswire)
Jun-21-23 07:30AM	Amesite CEO Dr. Ann Marie Sastry to Attend and Be Available for 1:1 Meetings at ISTELive 2023 (GlobeNewswire)
Jun-15-23 07:30AM	Amesite Announces Launch of Professional Upskilling Courses with Central Michigan University (GlobeNewswire)
07:30AM	Loading…
Jun-06-23 07:30AM	Announcing Amesite Founder and CEO, Dr. Ann Marie Sastry as Opening Keynote at CSOs Future of Cybersecurity Summit on June 8, 2023 (GlobeNewswire) -7.52%
Jun-02-23 07:30AM	Amesite to Participate in Live Benzinga All Access Event Today at 11am ET (GlobeNewswire)
May-31-23 07:30AM	Amesite Announces Successful Completion of Pilot Program under NAFEO Alliance at Benedict College in South Carolina (GlobeNewswire)
May-18-23 07:30AM	Amesite Announces Partnership Renewal with EWIE Group of Companies (GlobeNewswire) +11.94%
07:06AM	Amesite Third Quarter 2023 Earnings: US$0.37 loss per share (vs US$1.12 loss in 3Q 2022) (Simply Wall St.)
May-10-23 12:45PM	What Does Amesite's V6 Platform Do? One Month Since Its Launch, A Look At The eLearning Company's Product (ACCESSWIRE)
May-09-23 07:30AM	Amesite Inc. to Present at Sidoti Virtual Investor Conference May 10, 2023 (GlobeNewswire)
07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-27-23 12:41PM	10 Most Promising AI Stocks (Insider Monkey) +16.10%
07:30AM	Amesite Announces Partnership Renewal with Michigan Works! Southeast (GlobeNewswire)
Apr-18-23 07:30AM	Amesite Demonstrates AI Content Generation with AI Narration on its V6 Platform, Showing How Any Customer Can Scale Offerings (GlobeNewswire) -14.03%
Apr-17-23 12:55PM	The Economy Is Changing Fast; This Education Company Is Getting Students Prepared (ACCESSWIRE) -7.34%
Apr-14-23 09:44AM	Amesite CEO Dr. Ann Marie Sastry to Be a Panelist at the National Action Network 2023 Convention, Representing the NAFEO-Amesite Alliance, and to Be Available for 1:1 Meetings (GlobeNewswire)
Apr-13-23 07:30AM	Amesite CEO Dr. Ann Marie Sastry to Attend and Be Available for 1:1 Meetings at ASU+GSV Summit (GlobeNewswire) +35.41%
Apr-03-23 07:30AM	Amesite Launches V6 Platform, Enabling Any Customer to Leverage GPT-4 Powered Functionality for Learning and Training (GlobeNewswire) +79.69%
Mar-30-23 08:27AM	Amesite and NAFEO Alliance Announce Expansion to Twelve Member Universities (GlobeNewswire)
Mar-20-23 09:30AM	From Releasing A Public Course On Using ChatGPT To Leveraging The AI To Improve Company Efficiency Amesite (NASDAQ: AMST) Looks Ahead Of The Curve For Integrating ChatGPT (News Direct)
Mar-15-23 07:30AM	Amesite Announces FERPA and COPPA Compliance (GlobeNewswire)
Mar-13-23 03:32PM	Amesite Inc. (AMST) Confirms No Exposure to Silicon Valley Bank (GlobeNewswire)
Mar-09-23 05:00PM	Amesite Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements (GlobeNewswire) -8.36%
Mar-07-23 09:25AM	Insider Buying: AI Firm Amesite (NASDAQ: AMST) CEO Ann Marie Sastry Picks Up Company Stock Multiple Times, Has Never Sold Stock To Date (News Direct)
Mar-02-23 07:30AM	Amesite and Benedict College Launch Technology Upskilling Pilot Program to Learners Across Majors (GlobeNewswire) +5.63%
Feb-27-23 07:30AM	Amesite to Provide Video Shareholder Update February 27, 2023 at 1:00 PM ET (GlobeNewswire)
Feb-21-23 05:00PM	Amesite Inc. (NASDAQ: AMST) Announces 1-for-12 Reverse Stock Split Effective Pre-Market Opening on February 22, 2023 (GlobeNewswire)
12:10PM	7 AI Penny Stocks That Could Skyrocket in 2023 (InvestorPlace)
07:30AM	Amesite Inc. Launches Free Course on Generative AI: ChatGPT Fundamentals (GlobeNewswire)
Feb-16-23 07:30AM	Amesite Launches First Pilot Program under NAFEO Alliance at Benedict College in South Carolina (GlobeNewswire)
Feb-14-23 07:30AM	Amesite Announces GPT-3 Powered Functionality to Its AI Toolkit for Customers and Users (GlobeNewswire) +81.62%
Jan-25-23 07:30AM	Amesite Launches Case Study Video Highlighting the Delivery of Successful, Full Scale, Global Enterprise Learning Solution for EWIE Group of Companies (GlobeNewswire) +5.58%
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE) -20.00%
09:51AM	Amesite Inc. to Present at Sidoti Virtual Investor Conference January 18-19, 2023 (GlobeNewswire)
Jan-10-23 09:30AM	EdTech Company Amesite CEO Sits Down With Benzinga To Discuss 2022 Successes And The Vision For 2023, Building A Promising Future Of AI In Learning (News Direct) +10.90%
Dec-14-22 10:08AM	Amesite Announces Response to NIST RFI for Potential Semiconductor Manufacturing USA Institutes (GlobeNewswire)
Nov-22-22 09:15AM	This Purposeful Online Learning Company Is Forging Ahead (News Direct)
Nov-21-22 07:30AM	Amesite Named One of The Nations 2022 Best and Brightest in Wellness® and 2022 Best and Brightest Companies to Work For in The Nation® (GlobeNewswire) -17.55%
Nov-10-22 10:27AM	The Market Votes: Amesite Releases Study of E-Learning Success For Global Company (News Direct)
Nov-01-22 09:00AM	With Labor Market Still A Concern, Are There Endless Opportunities In The Online Learning Market For This Burgeoning AI Company? (News Direct)
Oct-17-22 07:30AM	Amesite Delivers Successful, Full Scale, Global Enterprise Learning Solution for EWIE Group of Companies with Case Study (GlobeNewswire) +6.21%
Oct-12-22 07:30AM	Amesite Named One of Michigans 2022 Best and Brightest in Wellness and Metro Detroits 2022 Best and Brightest Companies to Work For by the NABR (GlobeNewswire)
Oct-04-22 08:58AM	Companies Are Reporting Dropping Degree Requirements And Shifting To Skill-Based Hiring, But Credibility Still Looms As An Issue A Boon For Edtech Platform Players Like Amesite (NASDAQ: AMST)? (News Direct) +7.04%
Sep-27-22 02:02PM	EXCLUSIVE: CEO Of Edtech Company Amesite (NASDAQ: AMST) On Student Loan Forgiveness And More Loan Forgiveness Offers Some Relief Wanted But We Know It Does Not Solve The Root Problems (News Direct) -5.21%
Sep-15-22 07:30AM	Amesite and NAFEO Announce Addition of New Member Universities to Alliance (GlobeNewswire) +6.06%
Sep-09-22 07:30AM	Amesite Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022 (GlobeNewswire)
Sep-01-22 05:30PM	Amesite Announces Closing of $2.3 Million Registered Direct Offering (GlobeNewswire) -11.30%
Aug-30-22 05:30PM	Correction Notice to Press Release: Amesite Announces $2.3 Million Registered Direct Offering (GlobeNewswire) -51.45%
09:10AM	Amesite Announces $2.3 Million Registered Direct Offering (GlobeNewswire)
Aug-29-22 07:30AM	Amesite and NAFEO Announce Major Collaboration to Provide Professional Learning Support to Historically Black Colleges and Universities (GlobeNewswire) +9.43%
Aug-26-22 07:30AM	Amesite CEO Dr. Ann Marie Sastry Appeared Live on Newsy Tonight with Chance Seales on Thursday, August 25 at 8:00 p.m. ET (GlobeNewswire) -11.63%
Aug-25-22 07:30AM	Amesite and Conner Prairie Announce Launch of Conner Prairie Learning Portal, which includes a Digital Membership with the Ability to Reach Millions of Visitors (GlobeNewswire)
06:24AM	We're Not Very Worried About Amesite's (NASDAQ:AMST) Cash Burn Rate (Simply Wall St.)
Aug-23-22 07:30AM	Amesite Announces Partnership with Central Michigan University to Deliver a Complete Upskilling Solution (GlobeNewswire) +18.27%
Aug-22-22 08:14AM	AMST: Advanced technology company specializing in creating Learning Community Environments poised to disrupt the industry. The near-term potential exists for generating high-margin, recurring revenues (Zacks Small Cap Research) +21.53%
Aug-15-22 02:59PM	Amesite Inc. to Present at Investor Summit Group's Q3 Virtual Conference (Newsfile)
Aug-02-22 07:30AM	Amesite to Provide Website Integrated eCommerce Solution to Wayne State University, College of Engineering (GlobeNewswire)
Aug-01-22 04:47PM	Amesite Reports Partnering With Conner Prairie To Launch Next-Generation Educational Tools (News Direct)
Jul-06-22 10:00AM	Cloud Learning Market Heats Up With This New Development (News Direct) +6.78%
Jun-23-22 09:00AM	Why Amesite Believes It Is Positioning Itself To Dominate The Online Learning Market (News Direct)
Jun-22-22 07:30AM	Amesite Launches V5 Platform, Enabling Every Business, University and Museum to Deliver or Sell AI-Powered, Branded eLearning (GlobeNewswire)
Jun-02-22 07:00AM	Amesite Inc. Issues Shareholder Update (GlobeNewswire) +5.19%
May-27-22 10:06AM	Multiple insiders bought Amesite Inc. (NASDAQ:AMST) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
May-12-22 07:30AM	Amesite Announces Sponsorship of the ATD 2022 International Conference & Exposition (GlobeNewswire)
Apr-26-22 07:30AM	Amesite Inc. Announces Participation in Investor Summit Group's Q2 In-Person Conference (Newsfile) -7.52%
Apr-20-22 07:30AM	Amesite Announces 3 Year Partnership Renewal with Wayne State University (PR Newswire)
Apr-04-22 07:30AM	Amesite to Present at ASU+GSV Summit Today April 4 at 5:10 PM ET (PR Newswire)
Mar-23-22 12:11PM	Amesite Announces Partnership with Conner Prairie (PR Newswire)
Mar-11-22 08:00AM	Amesite Announces Contract for City University of New York in Professional Upskilling (PR Newswire) +5.91%
Feb-16-22 04:17PM	Amesite Announces Closing of Public Offering of Common Stock (PR Newswire)
Feb-15-22 12:28PM	Amesite to Present at Aegis Virtual Conference on February 24, 2022 (PR Newswire)
Feb-14-22 10:16PM	Amesite Increases Previously Announced Public Offering of Common Stock (PR Newswire) -13.93%
Feb-11-22 08:25PM	Amesite Announces Pricing of Public Offering of Common Stock (PR Newswire) -5.17%

Amesite, Inc. engages in the provision of customization and scalable online products for schools and businesses. The firm uses machine learning to provide a novel, mass customized experience to learners. The company was founded by Ann Marie Sastry on November 14, 2017 and is headquartered in Detroit, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sastry Ann Marie	CHIEF EXECUTIVE OFFICER	Dec 20 '23	Buy	1.85	10,000	18,500	542,098	Dec 21 10:16 AM

Open in Screener

GALT

Galectin Therapeutics Inc

Apr 25 • 04:00PM ET

3.50

Dollar change +0.21
Percentage change 6.38	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

GALT Galectin Therapeutics Inc daily Stock Chart

Held by: VTI VXF ONEQ MEDX IWC

Index	-	P/E	-	EPS (ttm)	-0.75	Insider Own	31.54%	Shs Outstand	61.85M	Perf Week	3.55%
Market Cap	216.65M	Forward P/E	-	EPS next Y	-1.59	Insider Trans	-0.11%	Shs Float	42.38M	Perf Month	47.68%
Income	-41.19M	PEG	-	EPS next Q	-0.16	Inst Own	11.68%	Short Float	6.46%	Perf Quarter	95.53%
Sales	0.00M	P/S	-	EPS this Y	10.81%	Inst Trans	-1.46%	Short Ratio	18.43	Perf Half Y	69.08%
Book/sh	-1.01	P/B	-	EPS next Y	-140.91%	ROA	-165.97%	Short Interest	2.74M	Perf Year	100.00%
Cash/sh	0.41	P/C	8.44	EPS next 5Y	-	ROE	-	52W Range	1.28 - 4.27	Perf YTD	110.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-14.30%	ROI	-357.52%	52W High	-18.00%	Beta	0.77
Dividend TTM	-	Quick Ratio	1.77	Sales past 5Y	0.00%	Gross Margin	-	52W Low	173.44%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	1.77	EPS Y/Y TTM	-13.92%	Oper. Margin	0.00%	RSI (14)	59.13	Volatility	11.91% 11.65%
Employees	14	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	11.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	9.67%	Payout	-	Rel Volume	1.43	Prev Close	3.29
Sales Surprise	-	EPS Surprise	-60.00%	Sales Q/Q	-	Earnings	Mar 29 BMO	Avg Volume	148.51K	Price	3.50
SMA20	5.79%	SMA50	38.61%	SMA200	77.11%	Trades		Volume	211,983	Change	6.38%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-20	Reiterated	H.C. Wainwright	Buy	$9 → $12
Feb-13-19	Initiated	B. Riley FBR	Buy	$11
Dec-07-17	Reiterated	H.C. Wainwright	Buy	$6 → $10
Nov-28-17	Reiterated	H.C. Wainwright	Buy	$3.50 → $6
Oct-19-17	Initiated	ROTH Capital	Buy
Mar-30-17	Upgrade	H.C. Wainwright	Neutral → Buy	$3.50
Oct-03-16	Downgrade	FBR & Co.	Outperform → Mkt Perform	$12 → $2
Sep-29-16	Downgrade	H.C. Wainwright	Buy → Neutral	$1.50
Sep-28-16	Downgrade	ROTH Capital	Buy → Sell
Mar-28-16	Resumed	H.C. Wainwright	Buy	$8
Sep-21-15	Initiated	H.C. Wainwright	Buy	$7
Aug-01-14	Downgrade	Aegis Capital	Buy → Hold
Jul-30-14	Reiterated	MLV & Co	Buy	$27 → $16
Jul-29-14	Reiterated	MLV & Co	Buy	$27 → $15
Apr-02-14	Reiterated	MLV & Co	Buy	$20 → $27
Feb-10-14	Reiterated	Aegis Capital	Buy	$16 → $32
Jan-09-14	Reiterated	Aegis Capital	Buy	$10 → $16
Dec-03-13	Initiated	MLV & Co	Buy	$20
Aug-19-13	Reiterated	Aegis Capital	Buy	$7 → $10

Show Previous Ratings

Apr-09-24 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis (GlobeNewswire) +5.35%
Apr-05-24 08:52AM	GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023 (InvestorPlace) +24.33%
Mar-29-24 09:11AM	Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments (GuruFocus.com)
08:00AM	Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development (GlobeNewswire)
11:11AM	Loading…
Nov-13-23 11:11AM	Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023 (GuruFocus.com) -7.14%
08:45AM	UPDATE Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update (GlobeNewswire)
08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update (GlobeNewswire)
Nov-03-23 08:00AM	Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2023, Hosted by the AASLD (GlobeNewswire)
Oct-23-23 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023 (GlobeNewswire)
Oct-12-23 08:00AM	Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors (GlobeNewswire)
Oct-03-23 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis (GlobeNewswire)
Sep-26-23 08:00AM	Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023 (GlobeNewswire)
Sep-13-23 05:22PM	Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 (GlobeNewswire) +6.70%
Sep-11-23 09:55AM	Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
08:00AM	Loading…
08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 (GlobeNewswire)
Sep-07-23 12:00PM	Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023 (GlobeNewswire) +7.32%
Aug-17-23 12:00PM	What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock (Zacks) +10.19%
Aug-14-23 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update (GlobeNewswire)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace)
May-15-23 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update (GlobeNewswire)
Apr-27-23 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Galectin Therapeutics Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases (GlobeNewswire)
Mar-30-23 08:00AM	Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.34%
Mar-16-23 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire)
Mar-02-23 08:00AM	Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) +8.29%
Jan-24-23 08:00AM	Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal (GlobeNewswire)
Jan-05-23 08:00AM	Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) -5.04%
Dec-13-22 09:55AM	Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now (Zacks)
Nov-29-22 08:00AM	Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders (GlobeNewswire)
08:00AM	Loading…
Nov-28-22 08:00AM	Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit (GlobeNewswire)
Nov-14-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update (GlobeNewswire) +5.56%
Nov-01-22 08:00AM	Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2022, Hosted by the AASLD (GlobeNewswire)
Oct-14-22 08:00AM	Galectin Therapeutics to Present in Upcoming Conferences (GlobeNewswire) +5.19%
Oct-12-22 08:00AM	Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer (GlobeNewswire)
Oct-06-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire)
Sep-08-22 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022 (GlobeNewswire) +5.65%
Aug-15-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update (GlobeNewswire) +5.31%
Jul-26-22 08:00AM	Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 (GlobeNewswire)
Jun-21-22 08:00AM	Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress 2022 (GlobeNewswire)
May-23-22 08:00AM	Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress (GlobeNewswire)
May-16-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) -7.35%
May-11-22 11:20AM	Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y (Zacks) -6.47%
May-03-22 08:30AM	Nano Dimensions Preliminary Q1/2022 Revenues: Approximately $10.5 Million (GlobeNewswire)
Apr-15-22 07:20AM	Is Galectin Therapeutics Inc. (NASDAQ:GALT) Popular Amongst Insiders? (Simply Wall St.)
Apr-14-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) +10.13%
Mar-31-22 08:00AM	Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update (GlobeNewswire) -5.85%
Jan-06-22 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-21 08:00AM	Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein (GlobeNewswire)
Dec-13-21 08:00AM	Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting (GlobeNewswire)
Nov-15-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update (GlobeNewswire)
Nov-05-21 04:24PM	UPDATE Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD (GlobeNewswire)
Oct-27-21 08:00AM	Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD (GlobeNewswire)
Oct-05-21 03:39PM	UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 (GlobeNewswire)
01:55PM	Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-21-21 08:00AM	Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein (GlobeNewswire)
Sep-09-21 09:00AM	Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-30-21 08:00AM	Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis (GlobeNewswire)
Aug-16-21 09:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update (GlobeNewswire)
Jul-30-21 04:28AM	Here's What Galectin Therapeutics Inc.'s (NASDAQ:GALT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jul-09-21 09:25AM	Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer (Benzinga) +25.00%
08:00AM	Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer (GlobeNewswire)
06:29AM	Galectin Therapeutics Soars on Positive Melanoma Treatment Data (TheStreet.com)
Jun-13-21 11:23PM	Is Galectin Therapeutics Inc. (GALT) A Good Stock To Buy? (Insider Monkey)
May-17-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update (GlobeNewswire)
Apr-27-21 09:28AM	Galectin Therapeutics to Present at 4th Global NASH Congress (GlobeNewswire)
Apr-19-21 08:00AM	World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Companys Galectin-3 Inhibitor, Belapectin (GlobeNewswire) +26.94%
Apr-15-21 09:00AM	Company News for Apr 15, 2021 (Zacks) -5.51%
Apr-14-21 08:28AM	Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response (Benzinga) +9.01%
Apr-13-21 07:01PM	Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy (GlobeNewswire)
Apr-06-21 08:00AM	Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study (GlobeNewswire) +35.27%
Mar-31-21 08:00AM	Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update (GlobeNewswire) +6.90%
Mar-08-21 08:00AM	OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy (GlobeNewswire)
Mar-04-21 08:00AM	Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) -6.44%
Jan-31-21 02:28AM	What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)? (Simply Wall St.)
Jan-19-21 11:15AM	Insider Sells Galectin Therapeutics Stock (Benzinga)
Dec-11-20 08:00AM	Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020 (GlobeNewswire)
Dec-04-20 04:17PM	Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation (GlobeNewswire)
Dec-01-20 08:00AM	Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders (GlobeNewswire)
Nov-09-20 08:00AM	Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020 (GlobeNewswire)
Nov-02-20 08:02AM	Galectin Therapeutics (NASDAQ:GALT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Oct-12-20 08:11AM	New Strong Sell Stocks for October 12th (Zacks)
Oct-06-20 03:30PM	These 2 Penny Stocks Could Quadruple (Or More), Says H.C. Wainwright (TipRanks)
Sep-29-20 12:00PM	Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today (GlobeNewswire) -9.34%
08:52AM	Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options (Zacks)
Sep-22-20 08:04AM	Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 (GlobeNewswire)
Sep-10-20 08:00AM	Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 (GlobeNewswire)
Sep-09-20 11:46AM	Insider Buys Galectin Therapeutics Stock (Benzinga) +6.79%
Sep-02-20 08:00AM	Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer (GlobeNewswire)
Aug-10-20 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update (GlobeNewswire)
Aug-03-20 12:48PM	Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jun-30-20 09:05AM	UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis (GlobeNewswire)
08:00AM	Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis (GlobeNewswire)
Jun-04-20 09:48PM	Hedge Funds Are Souring On Galectin Therapeutics Inc. (GALT) (Insider Monkey)
May-22-20 08:17AM	Galectin Therapeutics' Shares March Higher, Can It Continue? (Zacks) +8.25%
May-11-20 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update (GlobeNewswire)
May-04-20 08:37AM	Companies Like Galectin Therapeutics (NASDAQ:GALT) Are In A Position To Invest In Growth (Simply Wall St.) +8.52%
Apr-30-20 09:00AM	Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis (GlobeNewswire) -8.97%
Apr-02-20 08:04AM	Galectin Therapeutics Update on the Impact of COVID-19 (GlobeNewswire) -7.26%
Mar-16-20 08:00AM	Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update (GlobeNewswire) -17.41%

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEWIS JOEL	President and CEO	Apr 24 '24	Buy	3.39	1,000	3,390	2,000	Apr 25 01:27 PM
CZIRR JAMES C	10% Owner	Apr 23 '24	Sale	3.06	3,677	11,252	5,922,207	Apr 25 11:36 AM
FREEMAN KEVIN D	Director	Apr 22 '24	Buy	2.98	2,500	7,450	25,969	Apr 22 04:04 PM
CZIRR JAMES C	10% Owner	Apr 22 '24	Sale	3.06	21,323	65,248	5,925,884	Apr 25 11:36 AM
ELDRED KARY	Director	Jan 16 '24	Buy	1.79	500	893	49,313	Jan 16 11:23 AM
Uihlein Richard E	Director	Sep 26 '23	Option Exercise	4.49	2,236,204	10,033,020	10,235,495	Sep 27 02:03 PM
ELDRED KARY	Director	Jul 19 '23	Buy	1.79	1,598	2,854	48,813	Jul 20 07:40 AM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

AMST

Amesite Inc

GALT

Galectin Therapeutics Inc

Upgrade your FINVIZ experience